2022
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
Marczyk M, Qing T, O’Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. Npj Breast Cancer 2022, 8: 88. PMID: 35869114, PMCID: PMC9307813, DOI: 10.1038/s41523-022-00449-3.Peer-Reviewed Original ResearchTumor immune microenvironmentImmune microenvironmentTriple-negative breast cancer tissuesTriple-negative breast cancerAfrican AmericansImmune checkpoint inhibitorsTumor mutation burdenNegative breast cancerBreast cancer tissuesImmune-related pathwaysStromal TILsCheckpoint inhibitorsImmune exclusionClinical outcomesPD-L1Self-identified African AmericansCancer patientsImmune infiltrationBreast cancerMutation burdenCancer tissuesPredictive signatureMRNA expressionTherapeutic agentsPatients
2021
P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients
Moutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, Wei W, Pusztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients. Journal Of Thoracic Oncology 2021, 16: s405-s406. DOI: 10.1016/j.jtho.2021.01.671.Peer-Reviewed Original Research
2018
Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information
Wei W, Sun Z, da Silveira W, Yu Z, Lawson A, Hardiman G, Kelemen L, Chung D. Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. Statistical Methods In Medical Research 2018, 28: 2137-2149. PMID: 29336210, PMCID: PMC6922004, DOI: 10.1177/0962280217752980.Peer-Reviewed Original ResearchConceptsCancer subgroupsAustralian Ovarian Cancer StudyHigh-grade serous ovarian cancerCancer patient subgroupsSerous ovarian cancerMolecular featuresOvarian Cancer StudyCancer Genome AtlasSurvival outcomesTreatment of cancerCancer patientsPatient subgroupsOvarian cancerPersonalized treatmentCancer progressionGenome AtlasCancer studiesKey molecular featuresSubgroupsCancerClear benefitTreatmentPatientsClinicians